Karl D. Kieburtz, M.D., M.P.H.

Karl D. Kieburtz, M.D., M.P.H.

Contact Information

Center for Human Exp. Therapeutics
Box 694
265 Crittenden Blvd.
Rochester, NY 14642

Appointment: (585) 275-URMC (8762)

  • Accepting New Patients Accepting New Patients
  • Admits to Strong Memorial Hospital Admits to Strong Memorial Hospital
  • Admits to Highland Hospital Admits to Highland Hospital

Professional Bio

Karl Kieburtz, MD, MPH, is the T1 Translation Key Function Director and the Director of the Center for Human Experimental Therapeutics (CHET) at the URMC. He is the Robert J. Joynt Professor in Neurology and Professor of Community and Preventive Medicine and Environmental Medicine. CHET conducts learning phase clinical trials in a wide spectrum of disorders in collaboration with investigators within the University of Rochester Medical Center (URMC) as well as with colleagues throughout North America, Europe, Asia and Oceania. Dr Kieburtz's primary clinical and research interests are neurodegenerative diseases affecting the basal ganglia, particularly Parkinson disease, Huntington disease, and HIV related neurologic disorders. He is the principal investigator for the NINDS sponsored trials of neuroprotective agents for PD (NET-PD) and directs the Coordination Center for an NEI-funded consortium in Neuro-opthalmology.

He completed his MD and MPH degrees at the University of Rochester, as well as his Neurology residency and a fellowship in Experimental Therapeutics.

Awards & Honors (Local)

HONORS: Phi Beta Kappa, Amherst College, 1980; Frank Dow Award in Chemistry, Amherst College, 1980; Logan Clendenning Fellowship in the History of Medicine, 1982; George W. Merck Dean's Teaching Scholar, University of Rochester School of Medicine 1994-1997; The Best Doctors in America, Woodward/White, Inc., 2nd edition, 1994
Deprenyl and Tocopherol Antioxidant Therapy of Parkinsonism (DATATOP) NS24778 | NINDS, NIH 11/89-4/94 | Medical Director and Steering Committee member
Dideoxyinosine treatment of AIDS Dementia | Industry Sponsored Clinical Trial 10/90-11/91 | Principal Investigator
Parkinson Study Group START Clinical Trials | Industry Sponsored 11/1/90-4/30/92 | Medical Director and Steering Committee member
AIDS Clinical Trial Group | National Institute of Allergy and Infectious Disease, NIH | Member, Neurology Core Committee 7/90-7/94, 2UO1AI27658
Parkinson Study Group ROADS Clinical Trial | Industry Sponsored | Medical Director and Steering Committee member 4/92-4/94
BLIND-DATE Clinical Trial | Industry Sponsored | Medical Director, Parkinson Study Group 3/93-1/95
Glutamate Antagonist Tolerability in Huntington's Disease | Industry Sponsored Clinical Trial | Principal Investigator 7/1/93-6/30/94
STEP-UP Clinical Trial | Industry Sponsored | Medical Director, Parkinson Study Group 10/93-6/95
European Network for Striatal Transplantation in Huntington's Disease(NEST-HD):preclinical development & clinical trial method | European Economic Community | Sub-proposer and Consultant
Experimental Therapeutics of HIV Neurology (part of Neurologic AIDS Research Consortium Program Project, David Clifford, PI) | NINDS, NIH | Site Principal Investigator 12/1/93-11/30/95
SEESAW Clinical Trial | Industry Sponsored | Medical Director, Parkinson Study Group 11/93-12/95
Dana Foundation Consortium For The Treatment of HIV Dementia And Related Disorders | Co-Principal Investigator (L Epstein PI) 1/94-12/96
A Double Blind Study of Amitriptyline and Mexilitine for Painful HIV Neuropathy | AIDS Clinical Trials Group, Protocol 242, 2/94-2/96 | Study Chair
Clozapine for Psychosis in PD | FDA, Orphan Drug Div. | Medical Director (J Friedman PI) 7/94-6/97
Investigation of Tolerability of OPC-14117 in Huntington's Disease | Otsuka Pharmaceuticals | Medical Director (I Shoulson PI) 9/94-9/95
Trial of a Glutamate Antagonist in PD and MSA | Industry Sponsored | Principal Investigator 9/95-9/96
Evaluation of SPECT Imaging in The Diagnosis of PD | Industry Sponsored | Director of Coordination Center (K Marek PI) 9/95-9/96
Comparison of Levodopa and a Dopamine Agonist in PD | Industry Sponsored | Director of Coordination Center (I Shoulson PI) 10/95-10/02
PSG PRIME: Study of a Dopamine Agonist in Minority Persons | Industry Sponsored | Director of Coordination Center (C Tanner PI) 10/95-3/97
TACT Study: Treatment of ADHD in Children with Tourette's | NIH NINDS, RO1 NS33654 | Director of Coordination Center (R Kurlan, PI) 7/96-7/99
PSG SPIRAL Study: Interaction Study of Remacemide and Levodopa in Parkinson's Disease | Industry Sponsored | Principal Investigator 10/96-11/97
Clinical Trials Unit in HIV Dementia | NINDS, NIH, P01 NS32228 | Project PI (D Clifford, U of Washington, PPG PI) 12/93-4/02
Co-Enzyme Q10 and Remacemide Evaluation in Huntington's Disease | NIH, RO1 NS35284 | Principal Investigator 5/97-5/01
Neurocognitive Function, HIV Load and Surrogate Markers (NEAD) | NIH, P01 NS36519-01A1 | Data Management Core Director (L Epstein PI) 2/98-1/03
Earlier vs. Later L-dopa in Parkinson's Disease | NIH, R01 NS34796-01A1 | Coordination Center Director (S Fahn PI) 6/98-6/01
Effects of Coenzyme Q10 in Patients With Early, Untreated Parkinson's Disease | NIH R01 NS36714 | Co-Principal Investigator (C Shults PI) 6/98-6/01
Midcareer Investigator Award in Patient-Oriented Research | NINDS, NS02122 | Principal Investigator 1/99-12/04
ERSET: A Multi-center Randomized Clinical Trial for Early Treatment of Epilepsy | NIH, NS37897 | Coordination Center Director (J Engel PI) 7/99-6/07
Alzheimer's Disease Cooperative Study | 5U01-AG010483 | Chair, Safety Monitoring Committee (L Thal, PI) 9/01-6/12
PSG PATCH Study: Topical Dopamine Agonist in PD | Industry Sponsored | Coordination Center Director 6/99-12/00
PSG RAPID Study: Monoamine Oxidase Inhibitor in PD | Industry Sponsored | Coordination Center Director 10/97-10/00
Ethylester of Levodopa in PD | Industry Sponsored | Coordination Center Director 6/99-6/02
Early Randomized Surgical Epilepsy Trial | NIH R21 NS42372 | Coordination Center Director (J Engel PI) 7/01-6/06
Targeted Neuroprotection for HIV-1 Associated Neurologic Disease | NIH PO1 MH64570 | Project Co-PI (H Gelbard PI) 7/01-6/05
Neuroprotection Studies in PD: A Coordinating Center | NIH, NINDS NS43128 | Principal Investigator 9/01-7/06
Neurobiological Predictors of Huntington's Disease (PREDICT-HD) | NINDS NS40068 | Coordination Center Director (J Paulsen PI) 11/01-10/06
Prospective Huntington At-Risk Observational Study (PHAROS) | Huntington's Disease Society of America & Hereditary Disease Fdn | Coordination Center Director (I Shoulson, PI) 5/99-12/01
Prospective Huntington At-Risk Observational Study (PHAROS) | NIH / NHGRI / NINDS R01HG02449 | Coordination Center Director (I Shoulson, PI) 9/30/02-6/30/07
HSG Trend Study: A multicenter placebo-controlled efficacy and safety trial of an experimental membrane-stabilizing drug | ethyl-EPA in ambulatory Huntington's Disease patients | Coordination Center Director (I Shoulson, PI) 3/05-6/08
HSG DOMINO Study: Double blind study of minocycline in Huntington's disease | FD-R-02588 | Coordination Center Director (M Cudkowicz, PI) 8/05-8/08
Multi-Center Phase 1-2A Open-Label Dose-Escalation & Randomized, Double-Blind, Placebo-controlled Study of Dimebon in Subjects | w/ HD (DIMOND) Industry Sponsored | Principal Investigator 2/06-5/07
PSG Prami BID Study: A randomized, double-blind, active and placebo controlled, efficacy study of pramipexole in subjects w/ PD | Industry Sponsored | Principal Investigator 3/1/06-1/08
The University of Rochester's Clinical and Translational Science Institute | UL1 RR024160, KL2 RR024136, TL1 RR024135 | Instructor (T Pearson, PI) 9/06-6/11
Neuroprotection Studies in PD: A Coordinating Center | NIH, NINDS NS43128 | Principal Investigator 12/1/06-11/30/11
Midcareer Investigator Award in Patient-Oriented Research | NINDS, NS02122 | Principal Investigator 1/99-12/04
Data Coordination and Biostatistics Center for the NORDIC Network | National Eye Institute, 1U10 EYO17387-01A1 | Principal Investigator 02/10/09 – 01/31/14
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Safety and Efficacy Study of Dimebon in Patients with Mild-to-Moderate | Huntington Disease (HORIZON): Medivation | Principal Investigator 3/15/09-3/15/11
A multi-center, N.A., randomized, double-blind, parallel group study comparing three doses of ACR16... (HART) | NeuroSearch Sweden AB | Principal Investigator 11/1/07-3/31/10
Inosine for Parkinson's Disease: Safety and Trial Design Optimization | Michael J. Fox Foundation Rapid Response Innovation Award | Principal Investigator, Data Coordination Ctr 2/15/08-2/14/12
Coordination and Statistics for CoQ10 in HD (2CARE) | NIH NINDS RO1 NS052619 | Co-Principal Investigator (M McDermott, PI) 9/1/05-8/30/09
Prophylactic Phenobarbital after Resolution of Neonatal Seizures (PROPHENO) | NICHD, RO1 HD057977 | Steering Committee (R Guillett, PI) 12/01/2008 – 11/30/2013
Ethics of Sham Surgery Controls to Test Novel Parkinson's Disease Interventions | Michael J. Fox Foundation Rapid Response Innovation Award | Principal Investigator 11/07-05/08
PSG PRECEPT study, CEP1347 in Early PD | Industry Sponsored | Coordination Center Director (I Shoulson, PI) 12/01-8/04

Current Appointments

Senior Associate Dean, Clinical Research - Department of Dean's Office, SMD (SMD)
Director - Clinical & Translational Science Institute - Primary Administrative
Robert J. Joynt Professorship in Neurology - Department of Neurology (SMD)
Professor - Department of Neurology, Center for Human Experimental Therapeutics (SMD) - Primary
Professor - Department of Environmental Medicine (SMD)
Professor - Department of Public Health Sciences (SMD)

Specialties

Neurology - American Board of Psychiatry and Neurology

Education

MD | Medicine | Univ Rochester Sch Med/Dent1985
M.P.H. | University of Rochester1985
BA | Neuroscience and Religion | Amherst College1980

Post-Doctoral Training & Residency

Residency in Family Practice at University of Rochester Medical Center07/01/1986 - 07/01/1989
Internship in Neurology at Highland Hospital of Rochester06/17/1985 - 06/22/1986